Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
Regulation Reimbursement

Valuing Genzyme: A Health Care Reform Premium

This article was originally published in RPM Report

  • Analysis

Executive Summary

Sanofi has gone public with an $18.5 billion bid for Genzyme, but investors assume the French company is willing to go higher. So the question everyone is asking is, How much is Genzyme worth? The answer should include a premium for the special treatment the company will get under the health care reform law in the US.
Table

View full table

Advertisement

Related Content

Pink Sheet
Price Controls in Action: Understanding the Rise of the 340B Program
Pink Sheet
Job One for Big Pharma: Repositioning in DC Post-Health Care Reform
In Vivo
Sanofi/Genzyme: Emblematic of What Big Pharma's Buying Now
Pink Sheet
Taking Lumps From Health Care Reform
Pink Sheet
Taking Lumps From Health Care Reform
In Vivo
Orphaned No Longer: Big Pharma Embraces Drugs for Niche Markets
Pink Sheet
Big Pharma and Orphan Drugs: The Case for Thinking Small
Pink Sheet
Big Pharma and Orphan Drugs: The Case for Thinking Small
In Vivo
Health Care Reform and Business Development: 10 Reasons It Matters
Pink Sheet
Health Care Reform and Business Development: 10 Reasons it Matters

Topics

Related Companies

Advertisement
Tags:
Regulation Reimbursement
UsernamePublicRestriction

Register

PS080742

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By